Lisa McGrath,

Lisa McGrath,

Lisa McGrath

Lisa McGrath is Vice President of Human Resources at Surface Oncology. Lisa brings 20 years of experience driving impactful HR initiatives, including targeted recruitment, performance management, competency development and employee engagement for publicly traded, VC and angel funded companies. Prior to Surface, she ran her own customized human resource practice specializing in biotech, pharmaceutical, medical device and molecular diagnostics. Her clients included Leap Therapeutics, Minerva Neurosciences, Madrigal Pharmaceuticals, Good Start Genetics, Crestovo LLC and Agenus Bio. In addition to her consulting practice, Lisa has held senior HR leadership positions at Synta Pharmaceuticals, Intelligent Medical Devices, Predictive BioSciences and BioSphere Medical.

Lisa attended the University of Massachusetts and received a Bachelor’s Degree from Notre Dame College.

Chris Klee

Chris Klee

Chris Klee

Chris Klee is the Chief Financial Officer for Novartis US. Chris joined Novartis in 1993 as a Business Planning Analyst and has held a number of increasingly senior positions in the Pharma division. In 2005, Chris joined Novartis Institutes for BioMedical Research (NIBR) as Chief Financial Officer and later assumed an expanded role as Chief Operations Officer. Most recently, Chris served in a dual capacity as Chief Operating Officer for NIBR and Country Chief Financial Officer for Novartis US. Chris graduated from the Business School of The University of St. Gallen with a degree in Finance and Economics.

Jedd Wolchok, MD, PhD

Jedd Wolchok, MD, PhD

Jedd Wolchok, MD, PhD

Jedd Wolchok, MD, PhDJedd Wolchok is Chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center. His insight and innovation have placed him at the leading edge of cancer immunotherapy in two different roles: An active clinician-scientist exploring innovative immunotherapeutic strategies in laboratory models, and a principal investigator in numerous pivotal clinical trials. His specific research interest is the pre-clinical and early clinical development of novel immunologic therapies. Most recently, Dr. Wolchok has initiated several clinical trials using plasmid DNA vaccines for patients with melanoma. He has been involved in the development of the DNA vaccine program at every level – from initial studies in mouse models, through all levels of regulatory review, and now as principal investigator of the clinical trials. He earned his undergraduate degree from Princeton, and received both his MD and PhD from New York University.

David Tuveson, MD, PhD

David Tuveson, MD, PhD

David Tuveson, MD, PhD

David Tuveson, M.D., Ph.D. David Tuvseon is the Director of the Cancer Center and Cancer Therapeutics Initiative at Cold Spring Harbor Laboratory (CSHL), where he also serves as the Roy J. Zuckerberg Professor of Cancer Research, the Director of the Lustgarten Foundation Pancreatic Cancer Research Laboratory, and the Lustgarten Foundation’s Director of Research. Dr. Tuveson is a recognized leader in the study of pancreatic cancer and the role of the tumor microenvironment in promoting tumor growth. During his postdoctoral years, he co-developed KIT inhibitors for gastrointestinal stromal tumors with George Demetri, and created several KRAS- dependent mouse cancer models with Tyler Jacks. His lab also generated the first mouse models of ductal pancreatic cancer at the University of Pennsylvania. AT CSHL, Dr. Tuveson pioneered the development of human organoid models of pancreatic cancer, and his team is using these models to explore early detection methods and new therapeutic strategies. He earned his undergraduate degree from MIT, and received both his MD and PhD from Johns Hopkins University.

Jeff Goater

Jeff Goater

Jeff Goater

Jeff GoaterJeff oversees the Business Development, Finance and External Communication functions at Surface Oncology. He is a seasoned financial and business development executive with over 15 years of experience. Prior to Surface, he was the CFO of Voyager Therapeutics where he led multiple functions, including finance and business development, for the company. At Voyager, Jeff led the company through multiple strategic collaborations and financings, including an $845 million partnership with Sanofi Genzyme and a $73 million IPO. Previously, Jeff spent nearly a decade on Wall Street, where he was most recently a Managing Director at Evercore Partners where he advised on more than $100 billion in M&A and licensing transactions. Jeff began his career as a research scientist in the fields of musculoskeletal biology and gene therapy. He serves on the Board of Vaccinex. Jeff earned his B.A. in Biology, M.S. in Microbiology / Immunology, M.S. in Pathology / Molecular Medicine as well as his M.B.A. from the University of Rochester.